FilingReader Intelligence
Shilpa Medicare first globally to launch novel NAFLD treatment
August 9, 2025 at 05:29 AM UTC•By FilingReader AI
Shilpa Medicare Limited received approval from India's Central Drugs Standard Control Organization for Nor Ursodeoxycholic Acid tablets to treat Non-Alcoholic Fatty Liver Disease.
The approval makes Shilpa the first company globally to launch this novel NAFLD treatment. NAFLD affects an estimated 1.2 billion people worldwide and 188 million individuals in India.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:SHILPAMED•Bombay Stock Exchange
News Alerts
Get instant email alerts when Shilpa Medicare publishes news
Free account required • Unsubscribe anytime